BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8391067)

  • 1. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections.
    Fox EP; Weathers TD; Williams SD; Loehrer PJ; Ulbright TM; Donohue JP; Einhorn LH
    J Clin Oncol; 1993 Jul; 11(7):1294-9. PubMed ID: 8391067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.
    Coogan CL; Foster RS; Rowland RG; Bihrle R; Smith ER; Einhorn LH; Roth BJ; Donohue JP
    Urology; 1997 Dec; 50(6):957-62. PubMed ID: 9426730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
    Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
    Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary management of postchemotherapy testis cancer.
    Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
    Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
    Djaladat H; Nichols C; Daneshmand S
    Ann Surg Oncol; 2012 Jul; 19(7):2388-93. PubMed ID: 22395993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
    Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
    Nguyen CT; Stephenson AJ
    Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
    BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
    Beck SD; Foster RS; Bihrle R; Donohue JP; Einhorn LH
    Cancer; 2007 Sep; 110(6):1235-40. PubMed ID: 17665498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
    Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
    Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
    Spiess PE; Tannir NM; Tu SM; Brown GA; Liu P; Kamat AM; Wood CG; Evans JG; Pisters LL
    Cancer; 2007 Dec; 110(12):2700-8. PubMed ID: 17948916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
    Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer.
    Antonelli L; Ardizzone D; Tachibana I; Adra N; Cary C; Hugar L; Sexton WJ; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Cazzaniga W; Nicol D; Gerdtsson A; Tandstad T; Fizazi K; Fankhauser CD;
    J Clin Oncol; 2023 Dec; 41(34):5296-5305. PubMed ID: 37656935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival analysis of pure seminoma at post-chemotherapy retroperitoneal lymph node dissection.
    Rice KR; Beck SD; Bihrle R; Cary KC; Einhorn LH; Foster RS
    J Urol; 2014 Nov; 192(5):1397-402. PubMed ID: 24813309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
    Heidenreich A; Thüer D; Polyakov S
    Eur Urol; 2008 Feb; 53(2):260-72. PubMed ID: 18045770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation.
    Cary C; Pedrosa JA; Jacob J; Beck SD; Rice KR; Einhorn LH; Foster RS
    Cancer; 2015 Dec; 121(24):4369-75. PubMed ID: 26371446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection.
    Beck SD; Foster RS; Bihrle R; Koch MO; Wahle GR; Donohue JP
    J Urol; 2001 May; 165(5):1517-20. PubMed ID: 11342909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex treatment of residual metastatic germ cell cancer: A single center experience.
    Fazekas FE; Ujfaludi Z; Biró K; Páhi ZG; Buzogány I; Sükösd F; Pankotai T; Beöthe T
    J Biotechnol; 2024 Jun; 389():61-67. PubMed ID: 38692356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.